Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.09 -3.0%	$2.96	$1.05 ▼ $3.97	$357.75M	1.92	757,165 shs	306,653 shs
BNTC Benitec Biopharma	$13.21 +1.7%	$12.53	$8.06 ▼ $17.15	$340.99M	0.4	43,150 shs	61,190 shs
QNCX Quince Therapeutics	$1.58 -3.1%	$1.65	$0.61 ▼ $2.45	$87.55M	1.02	204,514 shs	105,383 shs
ZYBT Zhengye Biotechnology	$8.00 +14.6%	$6.50	$3.50 ▼ $14.30	$329.22M	N/A	139,516 shs	137,872 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	+0.80%	-3.65%	+31.06%	+3.09%
BNTC Benitec Biopharma	0.00%	-0.15%	+16.19%	-1.52%	+43.54%
QNCX Quince Therapeutics	0.00%	-3.55%	-11.89%	+46.85%	+146.97%
ZYBT Zhengye Biotechnology	0.00%	-7.06%	+25.77%	-18.17%	+697,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.7625 of 5 stars	3.5	1.0	0.0	0.0	2.0	0.8	0.6
BNTC Benitec Biopharma	1.375 of 5 stars	3.6	1.0	0.0	0.0	1.5	0.8	0.0
QNCX Quince Therapeutics	2.8156 of 5 stars	3.7	3.0	0.0	0.0	3.0	0.8	0.6
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	151.22% Upside
BNTC Benitec Biopharma	3.13	Buy	$26.00	96.82% Upside
QNCX Quince Therapeutics	3.30	Buy	$8.14	415.37% Upside
ZYBT Zhengye Biotechnology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNCX, ZYBT, ADCT, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
8/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/12/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$9.00 ➝ $8.00
8/5/2025	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/5/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00
8/5/2025	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$9.00
7/17/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/13/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.90	N/A	N/A	($2.10) per share	-1.47
BNTC Benitec Biopharma	$80K	4,334.53	N/A	N/A	$4.68 per share	2.82
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$0.69 per share	N/A
ZYBT Zhengye Biotechnology	$25.53M	14.78	$0.12 per share	67.74	$1.02 per share	7.84

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.57	N/A	N/A	-220.00%	N/A	-53.73%	11/6/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
QNCX Quince Therapeutics	-$56.83M	-$1.09	N/A	N/A	N/A	-187.49%	-42.47%	11/12/2025 (Estimated)
ZYBT Zhengye Biotechnology	$1.55M	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest QNCX, ZYBT, ADCT, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	-$0.50	-$0.14	-$0.50	$17.82 million	$18.84 million
8/11/2025	Q2 2025	QNCX Quince Therapeutics	-$0.28	-$0.34	-$0.06	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.93	4.66
BNTC Benitec Biopharma	0.01	14.80	14.80
QNCX Quince Therapeutics	1.45	5.00	5.00
ZYBT Zhengye Biotechnology	0.01	1.31	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
BNTC Benitec Biopharma	52.19%
QNCX Quince Therapeutics	30.75%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
BNTC Benitec Biopharma	1.30%
QNCX Quince Therapeutics	16.80%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	112.50 million	106.42 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
QNCX Quince Therapeutics	60	53.71 million	44.69 million	Optionable
ZYBT Zhengye Biotechnology	278	47.17 million	N/A	N/A

QNCX, ZYBT, ADCT, and BNTC Headlines

Recent News About These Companies

Zhengye Biotechnology Holding Ltd trading resumes

August 22 at 9:45 AM | msn.com

Zhengye Biotechnology Holding Ltd trading halted, volatility trading pause

August 21, 2025 | msn.com

Zhengye Biotechnology (NASDAQ:ZYBT) Raised to Hold at Wall Street Zen

August 2, 2025 | marketbeat.com

ZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...

July 17, 2025 | wsj.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock News

July 3, 2025 | gurufocus.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results

July 3, 2025 | prnewswire.com

ZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron's

July 2, 2025 | barrons.com

ZYBT - Zhengye Biotechnology Holding Ltd Chart - Morningstar

June 27, 2025 | morningstar.comM

Zhengye Biotechnology Holding Ltd

June 21, 2025 | morningstar.comM

ZYBT Zhengye Biotechnology Holding Limited

May 30, 2025 | seekingalpha.com

Zhengye Biotechnology faces NASDAQ compliance issue

May 24, 2025 | investing.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing Requirements

May 23, 2025 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

May 23, 2025 | globenewswire.com

Should We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?

April 7, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Ltd.

April 3, 2025 | wsj.com

Zhengye Biotechnology Holding Limited (ZYBT)

March 27, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

January 14, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

January 8, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

January 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, ZYBT, ADCT, and BNTC Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.08 -0.10 (-2.99%)

Closing price 03:59 PM Eastern

Extended Trading

$3.13 +0.04 (+1.46%)

As of 07:46 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Benitec Biopharma NASDAQ:BNTC

$13.21 +0.22 (+1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$13.23 +0.02 (+0.15%)

As of 04:04 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Quince Therapeutics NASDAQ:QNCX

$1.58 -0.05 (-3.07%)

Closing price 04:00 PM Eastern

Extended Trading

$1.64 +0.05 (+3.48%)

As of 07:26 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Zhengye Biotechnology NASDAQ:ZYBT

$8.00 +1.02 (+14.61%)

As of 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time